Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Acta Microbiologica et Immunologica Hungarica

• Publication date

  2010-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1556/AMicr.57.2010.1.3PMID 20350877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Role of Serum and Tissue Matrix Metalloprotease-9 Expression in Chronic HCV Patients Treated with Pegylated IFN-α2b and Ribavirin

  2005cited by this paper
• Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B

  2005cited by this paper
• Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues.

  2005cited by this paper
• Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins

  2004cited by this paper
• Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells.

  2002cited by this paper
• Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis.

  2001cited by this paper
• Characterization of a Cell Line HFH-T2, Producing Viral Particles, from Primary Human Fetal Hepatocytes Infected with Hepatitis B Virus

  2001cited by this paper
• Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.

  2000cited by this paper
• Estimating future hepatitis C morbidity, mortality, and costs in the United States.

  2000cited by this paper
• Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma.

  2000cited by this paper
• Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.

  1999cited by this paper
• Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein.

  1999cited by this paper
• Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1

  1999cited by this paper
• Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis

  1999cited by this paper
• Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells.

  1999cited by this paper
• Retinoid‐Mediated Suppression of Tumor Invasion and Matrix Metalloproteinase Synthesis

  1999cited by this paper
• Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1.

  1999cited by this paper
• Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1.

  1999cited by this paper
• Matrix metalloproteinases.

  1998cited by this paper
• Dual expression of matrix metalloproteinase‐2 and membrane‐type 1‐matrix metalloproteinase in fibrotic human livers

  1997cited by this paper
• Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.

  1997cited by this paper
• Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease.

  1997cited by this paper
• Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

  1997cited by this paper
• Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3

  1996cited by this paper
• Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma.

  1996cited by this paper
• Elevated plasma levels of matrix metalloproteinase‐9 (92‐kd type IV collagenase/gelatinase B) in hepatocellular carcinoma

  1996influential reference
• Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential

  1996cited by this paper
• Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

  1996cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Expression Pattern of Matrix Metalloproteinases in Human Liver

  1995cited by this paper
• The Family of Matrix Metalloproteinasesa

  1994cited by this paper
• The family of matrix metalloproteinases.

  1994cited by this paper
• Effects of cytokines on the liver

  1991cited by this paper
• Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen.

  1990cited by this paper
• The "soluble sandwich" approach for immunoassays: methodological and instrumental implications.

  1990cited by this paper
• Hepatitis C virus in a prospective study of posttransfusion non‐A, non‐B hepatitis in Taiwan

  1990cited by this paper
• High metalloproteinase inhibitor content of human cirrhosis and its possible conference of metastasis resistance.

  1988cited by this paper
• Pathologic aspects of cirrhosis. A review.

  1977cited by this paper

• The Effect of Somatostatin on Mediators of Liver Inflammation and Fibrosis in Viral Cirrhosis

  2026cites this paper
• Propolis Nanoparticles Combined with Gamma-Irradiation Enhance the Potency of Anticancer Against HepG2 Cell Lines: Invitro Investigation

  2024cites this paper
• Diagnostic values of MMP-9 and TGF-1β in assessing the severity of liver fibrosis and the rate of its progression in patients with chronic hepatitis C GT 1 infection

  2023cites this paper
• Expression of matrix metalloproteinases in human cystic echinococcosis.

  2023cites this paper
• Enzymes of Fibrosis in Chronic Liver Disease

  2022cites this paper
• MMP9 and CEBPα Genes as a New Prognostic Biomarker for Hepatocellular Carcinoma Caused by Infection with HCV-Genotype (4)

  2021cites this paper
• Potential role of noninvasive biomarkers during liver fibrosis

  2021cites this paper
• Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases

  2021cites this paper
• Noninvasive Biomarkers for Liver Fibrosis

  2020cites this paper
• METABOLISM FEATURES OF HAPTOGLOBIN AS INFLAMMATION ACUTE PHASE PROTEIN IN PATIENTS WITH CHRONIC HCV INFECTION

  2020cites this paper
• Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1.

  2020cites this paper
• Direct Markers of Liver Fibrosis

  2019cites this paper
• The Molecular Effect of Curcumin Subsidized by Radiation on HepG2 cell lines

  2018influential citation
• Adiponectin attenuates profibrotic extracellular matrix remodeling following cardiac injury by up‐regulating matrix metalloproteinase 9 expression in mice

  2017cites this paper
• Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression

  2017cites this paper
• Dysregulated matrix metalloproteinases and tissue inhibitors of metalloproteinase in residual splenic tissue after subtotal splenectomy due to portal hypertension

  2017cites this paper
• Traditional Markers in Liver Disease

  2017cites this paper
• Serological diagnosis of liver fibrosis by quantitative estimation of serum biomarkers using Luminex xMAP assay

  2016cites this paper
• Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage.

  2016cites this paper
• Noninvasive Markers to Assess Liver Fibrosis

  2016cites this paper
• Pigment Epithelium-derived Factor and Matrix Metalloproteinase-9 in Liver Cirrhosis

  2016cites this paper
• Plasma Levels of Matrix Metalloproteinase (MMP)-2, MMP-9 and Tumor Necrosis Factor-α in Chronic Hepatitis C Virus Patients

  2015cites this paper
• Biomarcadores, índices y algoritmos para el diagnóstico de fibrosis hepática en pacientes con hepatitis crónica por virus C

  2015cites this paper
• Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma

  2015cites this paper
• Platelet Microparticles and Monocyte Platelet Aggregates: Crucial Components of Chronic Hepatitis C Pathway

  2014cites this paper
• Can Fibrogenesis Markers Reflect Early Hepatic Histopathology in Chronic Hepatitis C

  2014cites this paper
• Noninvasive Biomarkers of Liver Fibrosis: An Overview

  2014cites this paper
• Non-invasive Assessment of Liver Fibrosis Using Serum Markers

  2014cites this paper
• Results of the 4 th Scientific Workshop of the ECCO ( Group II ) : Markers of intestinal fibrosis in inflammatory bowel disease tps

  2014cites this paper
• Non invasive tools for the diagnosis of liver cirrhosis.

  2014cites this paper
• Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease.

  2014cites this paper
• Can brucellosis influence the course of chronic hepatitis C in dual infection?

  2013cites this paper
• Alterations in serum MMP and TIMP concentrations following chronic heroin abuse

  2013cites this paper
• Lower incidence of hepatic metastases of colorectal cancer in patients with chronic liver diseases: meta-analysis.

  2013cites this paper
• Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients.

  2012cites this paper
• Enhanced Exhalation of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Patients with COPD Exacerbation: A Prospective Study

  2012cites this paper
• Diagnostic value of non-invasive bio-markers for stage-specific diagnosis of hepatic fibrosis in patients with advanced schistosomiasis japonica.

  2011cites this paper
• Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma

  2011cites this paper
• Non-Invasive markers for hepatic fibrosis

  2011cites this paper
• Non-Invasive Biomarkers for Hepatic Fibrosis

  2011influential citation